stockrowJohnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Free cash flow margin
Johnson & Johnson's free cash flow margin over the twelve months to 30 September 2026 was 21.1%, down 0.6 percentage points from fiscal 2025 (21.7%). Over the past ten years it has ranged from 21.7% (fiscal 2025) to 28.3% (fiscal 2019) — the current reading is the lowest in ten years. That is above the Drug Manufacturers General industry median of 18.5% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 21.7% | (1.42) |
| FY2024 | 23.1% | 1.25 |
| FY2023 | 21.9% | (0.31) |
| FY2022 | 22.2% | (3.84) |
| FY2021 | 26.0% | 1.18 |
| FY2020 | 24.8% | (3.43) |
| FY2019 | 28.3% | 1.61 |
| FY2018 | 26.6% | 0.99 |
| FY2017 | 25.7% | 2.27 |
| FY2016 | 23.4% | (4.55) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GILD Gilead Sciences, Inc. compare | 44.5% |
| ABBV AbbVie Inc. compare | 28.6% |
| NVS Novartis AG compare | 24.7% |
| AMGN Amgen Inc. compare | 24.6% |
| LLY Eli Lilly and Company compare | 22.7% |
| JNJ Johnson & Johnson | 21.1% |
| PFE Pfizer Inc. compare | 18.5% |
| AZN AstraZeneca PLC compare | 10.2% |
| MRK Merck & Co., Inc. compare | 0.00% |
| Drug Manufacturers General industry median | 18.5% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement